CID 969510

Base Information

• Chemical Name: CID 969510
• CAS No.: 51333-22-3
• Molecular Formula: C25H34O6
• Molecular Weight: 430.59
• Hs Code.: 29372900
• European Community (EC) Number: 257-139-7
• Wikipedia: Budesonide
• Mol file: 51333-22-3.mol

Synonyms:Budesonide;Budesonide, (R)-Isomer;Budesonide, (S)-Isomer;Horacort;Pulmicort;Rhinocort;Tarpeyo

Chemical Property of CID 969510

Chemical Property:

• Appearance/Colour: white solid
• Vapor Pressure: 6.94E-17mmHg at 25°C
• Melting Point: 221-232 °C (dec.)
• Refractive Index: 1.592
• Boiling Point: 599.7 °C at 760 mmHg
• PKA: 12.87±0.10(Predicted)
• Flash Point: 201.8 °C
• PSA: 93.06000
• Density: 1.27 g/cm³
• LogP: 2.71680
• Storage Temp.: Store at RT
• Solubility.: Practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in ethanol (96 per cent).
• Water Solubility.: 21.53mg/L(temperature not stated)
• XLogP3: 2.5
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 4
• Exact Mass: 430.23553880
• Heavy Atom Count: 31
• Complexity: 862

Purity/Quality:

99% ^*data from raw suppliers

Budesonide ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 40-36/37/38-20/21/22
• Safety Statements: 22-36-26

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C
• Isomeric SMILES: CCC[C@@H]1O[C@H]2C[C@@H]3[C@H]4CCC5=CC(=O)C=C[C@]5([C@@H]4[C@@H](C[C@]3([C@]2(O1)C(=O)CO)C)O)C
• Recent EU Clinical Trials: Increase in inhaled corticosteroid dose vs triple therapy in T2-high asthma patients who remain uncontrolled with medium dose inhaled corticosteroids/long-acting β2 adrenergic combination: a real-life study. TRICORDA Study (Triple vs Inhalados CORticoides a Dosis Altas).
• Description: Budesonide (brand name: Pulmicort) is a synthetic corticosteroid medication. It is indicated for the maintenance and prophylactic treatment of asthma. It is also used for the long-term management of chronic obstructive pulmonary disease (COPD). It is also useful for the treatment of inflammatory bowel disease including Crohn’s disease, ulcerative colitis and microscopic colitis, and also for treating allergic rhinitis. It exhibits potent glucocorticoid activity and weak mineralocorticoid activity in vivo. It is effective in inhibiting the activities of multiple cell types and mediators participating in either allergic or non-allergic-mediated inflammation. Budesonide is a glucocorticoid and an agonist of glucocorticoid receptors (EC50 = 45.7 pM in a transactivation assay). It is selective for glucocorticoid over mineralocorticoid receptors (EC50 = 7,620 pM). Budesonide inhibits LPS-induced TNF-α release from human peripheral blood mononuclear cells (PBMCs; IC50 = 0.96 nM). It reduces levels of IL-1β and eotaxin in the lungs and the number of eosinophils and neutrophils in bronchoalveolar lavage fluid (BALF) in a rat model of ovalbumin-induced airway inflammation when administered at a dose of 3 mg/kg. Intracolonic administration of budesonide decreases colon wet weight and colonic myeloperoxidase (MPO) activity in a rat model of oxazolone-induced colitis. Formulations containing budesonide have been used in the treatment of Crohn''s disease, ulcerative colitis, allergic rhinitis, and asthma. Budesonide is composed of a 1:1 mixture of epimers of the 16,17-butylacetal, creating a chiral center. The 22R-epimer binds to the GR with higher affinity than does the 22S-epimer (Table 33.5). The butyl acetal chain provided the highest potency for the homologous acetal chains. Its rate of topical uptake into epithelial tissue is more than 100 times faster than that for hydrocortisone and dexamethasone. Approximately 85% of the IV administered dose of budesonide undergoes extensive first-pass hepatic metabolism by CYP3A4 to its primary metabolites, 6β-hydroxybudesonide and 16α-hydroxyprednisolone, which have approximately 1/100 the potency of budesonide. This is an important inactivation step in limiting budesonide's systemic effect on adrenal suppression.
• indications: Budesonide is a commonly used in the treatment of bronchial asthma clinical drug in China.it can be used for non-hormone-dependent or hormone-dependent asthma, and chronic asthmatic bronchitis. Or it is used for the treatment of seasonal allergic rhinitis and many years occurring allergic rhinitis and it is used for preventing polyps regeneration after the removal of nasal polyps . It can also be used to treat various skin diseases. Budesonide is a halogen-free, topically applied , adrenal corticosteroid,it has significant anti-inflammatory, anti-allergic, anti-itching and anti-exudative effects. Its local effects is the same as beclomethasone dipropionate , it is mainly used for bronchial asthma which in the past bronchodilator or an antiallergic agent can not well control. This product can relieve bronchial spasm, pulmonary inhalation has anti-inflammatory effects, long-term use is well tolerated, it can reduce oral glucocorticoid dosage, without systemic effects of corticosteroids. It has the same effect on Children and adults with asthma as beclomethasone dipropionate , it has good effect, and it can be tolerated in long-term use ,for glucocorticoid-dependent or glucocorticoid-independent patients, mist inhaled can control asthma attacks and can effectively relapse prevention, inhaled treatment for 3 to 6 months, improvement in lung function is shown,the number of acute episodes is reduced , recoverability of plasma corticosterone concentration is gradually increased, and the daily dose of oral corticosteroids can be reduced by 40% to 50%. Thus,for glucocorticoid-dependent asthma patients, especially in patients with a larger amount of dose,the product can be used as an ideal alternative to thedrug for oral administration. Glucocorticoid effects of budesonide are strong, but mineralocorticoid effects are weak . Animal tests show that the drug’s effects on glucocorticoid receptor affinity are 200 times of cortisone, anti-inflammatory effects when it is applied topically are 1,000 times of cortisone , and subcutaneous and oral anti-inflammatory effects are only 40 and 25 times stronger than cortisone .
• Uses: A non-halogenated glucocorticoid related to triamcinolone hexacetonide. Used as an antiinflammatory agent laxative, antineoplastic The oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatme Budesonide is a glucocorticoid steroid that activates the glucorcorticoid receptor with an EC50 value of 12.4 nM. Like other glucocorticoids, budesonide reduces inflammation and has utility in inflammatory diseases, like asthma and inflammatory bowel disease. Also like other glucocorticoids, budesonide may be abused by athletes.[Cayman Chemical]
• Indications: Budesonide is a synthetic corticosteroid having a potent glucocorticoid and weak mineralocorticoid activity. In standard in vitro and animal models, budesonide has an approximately 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical antiinflammatory potency than cortisol.
• Clinical Use: Recently, budesonide (Entecort EC) has been approved for the treatment of mildly to moderately active Crohn’s disease involving the ileum and/or ascending colon.
• Drug interactions: Potentially hazardous interactions with other drugs Aldesleukin: avoid concomitant use. Antibacterials: metabolism accelerated by rifamycins. Anticoagulants: efficacy of coumarins and phenindione may be altered. Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone. Antifungals: concentration of inhaled and oral budesonide increased by itraconazole and ketoconazole. Antivirals: concentration of inhaled, intranasal and rectal budesonide increased by ritonavir. Cobicistat: concentration possibly increased by cobicistat - increased risk of adrenal suppression. Grapefruit juice: concentration of oral budesonide increased - avoid. Vaccines: high dose corticosteroids can impair immune response to vaccines - avoid with live vaccines.